Ocera to Present at the 16th Annual Needham Healthcare Conference
March 27, 2017 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 27, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 21, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
Ocera Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 10, 2017 06:00 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., March 10, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy
March 08, 2017 08:05 ET
|
Ocera Therapeutics, Inc.
IV OCR-002 statistically significantly normalized ammonia faster than standard of care Ammonia reduction statistically significantly correlated with clinical improvement in HE symptoms Ocera plans...
Ocera to Present at the Cowen and Company 37th Annual Healthcare Conference
February 28, 2017 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
February 01, 2017 08:10 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated...
Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
January 30, 2017 07:00 ET
|
Ocera Therapeutics, Inc.
Primary and Secondary Endpoints Showed Trend and Dose-Related Clinical Benefit Although Not Statistically Significant Ammonia Scavenger OCR-002 Demonstrated Statistically Significant Reduction in...
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
January 05, 2017 09:05 ET
|
Ocera Therapeutics, Inc.
Data Support Feasibility of Oral OCR-002 as Maintenance Therapy for Patients with Hepatic Encephalopathy Company Plans to Initiate Phase 2a in H1 2017 with New Optimized Tablet Formulation PALO...
Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
November 10, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced its plans to...
Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update
November 02, 2016 09:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic...